5.5(top 5%)
2-year impact
5.7(top 5%)
3-year impact
5.4(top 5%)
5-year impact
2.6(top 10%)
10-year impact
2.8K(top 10%)
PR articles
26.1K(top 10%)
PR citations
65(top 10%)
PR h-index
72(top 10%)
h-index
5.9(top 5%)
extended IF
4.4(top 5%)
2-YI (article-only)
11.7(top 20%)
2-YI (review-only)
5.4(top 5%)
2-YI (no self-cite.)
3.3K
documents
37.5K
doc citations

Top Articles

#TitleJournalYearPR Citations
1Multiple primary tumours: challenges and approaches, a reviewESMO Open2017454
2NTRK gene fusions as novel targets of cancer therapy across multiple tumour typesESMO Open2016445
3Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trialESMO Open2020405
4Mechanisms of resistance to EGFR-targeted drugs: lung cancerESMO Open2016366
5Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkersESMO Open2022261
6Implementing TMB measurement in clinical practice: considerations on assay requirementsESMO Open2019256
7Mechanisms of action and rationale for the use of checkpoint inhibitors in cancerESMO Open2017252
8Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIANESMO Open2022237
9Cancer and liver cirrhosis: implications on prognosis and managementESMO Open2016215
10Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to managementESMO Open2018209
11Global cancer control: responding to the growing burden, rising costs and inequalities in accessESMO Open2018202
12Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and managementESMO Open2019191
13Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancersESMO Open2016187
14Cardiotoxicity of immune checkpoint inhibitorsESMO Open2017186
15Adolescents and young adults (AYA) with cancer: a position paper from the AYA Working Group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE)ESMO Open2021181
16Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studiesESMO Open2022163
17Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitorsESMO Open2019162
18STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohortESMO Open2020162
19Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatmentESMO Open2022161
20Biology of premature ageing in survivors of cancerESMO Open2017147
21Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trialESMO Open2020147
22Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trialsESMO Open2021136
23Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterationsESMO Open2021136
24Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohortESMO Open2016134
25The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapyESMO Open2020133
26Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of expertsESMO Open2021131
27Hallmarks of glioblastoma: a systematic reviewESMO Open2016128
28Targeting immune checkpoints in breast cancer: an update of early resultsESMO Open2017128
29First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year updateESMO Open2021128
30Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?ESMO Open2018127
31Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancerESMO Open2017122
32Challenge of cancer in the elderlyESMO Open2016120
33The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022ESMO Open2023120
34Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancerESMO Open2023118
35Activating HER2 mutations as emerging targets in multiple solid cancersESMO Open2017117
36Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfallsESMO Open2016114
37The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?ESMO Open2021108
38Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancerESMO Open2022104
39Anti-TIGIT therapies for solid tumors: a systematic reviewESMO Open2023104
40Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohortESMO Open2021102
41How I treat biliary tract cancerESMO Open2022101
42Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injuryESMO Open201799
43The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trialsESMO Open202196
44How we treat esophageal squamous cell carcinomaESMO Open202396
45Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysisESMO Open202295
46Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancerESMO Open201794
47Prospective experimental treatment of colorectal cancer patients based on organoid drug responsesESMO Open202193
48Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancerESMO Open202191
49Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literatureESMO Open201890
50Impact of COVID-19 on anxiety levels among patients with cancer actively treated with systemic therapyESMO Open202090